Masimo announces expanded partnership with Shenzhen Mindray for SET®
Category: #health  By Paroma Bhattacharya  Date: 2019-05-15
  • share
  • Twitter
  • Facebook
  • LinkedIn

Masimo announces expanded partnership with Shenzhen Mindray for SET®

With the invention of Signal Extraction Technology® (SET®), Masimo has established a new standard for pulse oximetry by presenting the ability to measure through motion and low perfusion.

The U.S. based medical device manufacturing company Masimo has reportedly announced that it has signed a purchase and license agreement with Shenzhen Mindray Bio-Medical Electronics Co., Ltd. to leverage Mindray’s SET® Measure-through Motion and Low Perfusion™ pulse oximetry – noninvasive, incessant measurement of oxygen saturation (SpO2), perfusion index (Pi), and pulse rate (PR),  – in monitoring devices.

Reportedly, the devices by Mindray which are equipped with SET® will be now available in select countries in the Middle East, Europe, the Commonwealth of Independent States, Asia-Pacific (excluding China), including Australia, India, and Russia.

With the invention of Signal Extraction Technology® (SET®), Masimo has established a new standard for pulse oximetry by presenting the ability to measure through motion and low perfusion. SET® has presented the highest sensitivity and specificity in detecting desaturation events and preventing false desaturation events during these conditions in a study which compared multiple pulse oximetry technologies.

SET® has reportedly launched latest frontiers in monitoring of patients during challenging conditions: outcome studies have shown that SET®, aided with clinical assessment, has facilitated clinicians to reduce retinopathy of prematurity (ROP) in neonates, improve critical congenital heart disease (CCHD) screening in infants, and reduce ICU transfers and rapid response team activations by continuously monitoring patients in post-surgical wards. Among all the studies, more than 100 independent and objective studies have demonstrated that SET® surpasses other pulse oximetry technologies. Masimo has continuously improved SET®, and recently announced that SpO2 precision specifications have now enhanced to 1.5 percent in conditions of motion and no motion for adult, pediatric, and newborn patients, weighing less than 3 kg, with RD SET™ sensors. 

The advantages of Masimo SET® are now available to clinicians leveraging devices of Mindray in several countries outside the U.S., where Mindray has provided SET® pulse oximetry in devices from Datascope since acquiring it in the year 2008.

Source credit: https://www.biospace.com/article/releases/masimo-and-mindray-announce-expanded-partnership/

http://www.masimo.com/company/news/news-media/#news-05b424de-a21b-4533-99c5-13f5ae2d3ed6



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
By Paroma Bhattacharya

Mirati Therapeutics, an oncology company that engages in the development of targeted therapies, recently released its clinical trial results for MRTX849. Reportedly, MRTX849 is a KRAS G12C inhibitor and the data from P...

Best Buy to offer free next-day delivery feature on various products
Best Buy to offer free next-day delivery feature on various products
By Paroma Bhattacharya

Online retailers are always launching new and attractive deals during the holiday season, as it grosses the highest sale time for the year. Several retailer rollout out attractive offers, such as discounts or complimen...

Nature Tech Corp partners with Aldevron for gene therapy manufacturing
Nature Tech Corp partners with Aldevron for gene therapy manufacturing
By Paroma Bhattacharya

The global cell and gene therapy sector is expected to witness a thriving period of growth over the forthcoming years. In fact, owing to the favorable growth conditions across the industry, numerous biotechnology and p...